Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck to Invest €50M in Bari Production Site

Published: Wednesday, May 21, 2014
Last Updated: Wednesday, May 21, 2014
Bookmark and Share
Company to invest €50 million in its Italian production site in respond to the rising demand for biopharmaceuticals.

The announcement was made by Karl-Ludwig Kley, Chairman of the Executive Board of Merck, during a press conference held today at the Bari plant, in the presence of the Italian Prime Minister Matteo Renzi, and of the President of the Italian Pharma Industries Association Farmindustria, Massimo Scaccabarozzi.

Within Merck Serono's global biotech production network, the Bari site is part of fill & finish operations alongside the facilities in Darmstadt and Aubonne (Switzerland). The drugs produced within this global network are seeing long-term growing demand, especially as regards those to treat infertility. The new production facility in Bari, southern Italy, is to be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials and ampoules (fill & finish).

"To make Merck fit for the future, we are also investing in modern, expanded production capacities in order to meet the rising demand for our drugs," said Kley, making reference to the "Fit for 2018" transformation and growth program. During his visit to the Bari site today, he explained the reasons for the investment: "This is part of our growth plans for Merck and for the Merck Serono division in particular here in Bari, where we have excellent conditions thanks to highly skilled employees and a very good infrastructure. Patients will also benefit from this investment as we secure the supply of drugs that improve the quality of life of people around the globe."

Merck generates more than half of the sales of its Merck Serono division with biotech products. Among others, the company is the world market leader in the treatment of infertility. Around two million babies of the five million born with the help of infertility drugs worldwide were conceived with the aid of Merck Serono products.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck, NewLink Genetics Enter Ebola Vaccine Agreement
Companies have entered an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.
Wednesday, November 26, 2014
Merck Announces $5 Billion Accelerated Share Repurchase
Merck announced that it has entered into an accelerated share repurchase agreement (ASR) with Goldman, Sachs & Co. to repurchase $5 billion of Merck’s common stock.
Wednesday, May 22, 2013
Fujifilm to Acquire Merck Biomanufacturing Network
FUJIFILM Corporation and Merck announces they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network.
Thursday, March 03, 2011
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!